DOCSLIB.ORG

Splicing Inhibition of U2AF Leads to Alternative Exon Skipping

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Splicing Inhibition of U2AF Leads to Alternative Exon Skipping Splicing inhibition of U2AF65 leads to alternative exon skipping Sunghee Choa, Heegyum Moona, Tiing Jen Loha, Ha Na Janga, Yongchao Liua, Jianhua Zhoub, Takbum Ohnc, Xuexiu Zhenga, and Haihong Shena,1 aSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Korea; bJiangSu Key Laboratory of Neuroregeneration, Nantong University, Nantong 226001, China; and cDepartment of Cellular & Molecular Medicine, College of Medicine, Chosun University, Gwangju 501-759, Korea Edited by Michael R. Green, University of Massachusetts Medical School, Worcester, MA, and approved June 11, 2015 (received for review January 11, 2015) U2 snRNP auxiliary factor 65 kDa (U2AF65) is a general splicing factor mutations in SMN2 pre-mRNA cause predominantly skipping of that contacts polypyrimidine (Py) tract and promotes prespliceo- exon 7, which produces SMNΔ7, a truncated and less stable pro- some assembly. In this report, we show that U2AF65 stimulates al- tein with reduced self-oligomerization activity. Alternative exon 7 ternative exon skipping in spinal muscular atrophy (SMA)-related splicing of SMN pre-mRNA was modulated by orchestrated RNA– survival motor neuron (SMN) pre-mRNA. A stronger 5′ splice-site protein and protein–protein interactions, secondary structures of mutation of alternative exon abolishes the stimulatory effects of RNA, and RNA sequences (25–27). Among the mutations on U2AF65. U2AF65 overexpression promotes its own binding only on SMN2 pre-mRNA, the most functionally understood one is the the weaker, not the stronger, Py tract. We further demonstrate C-to-U point mutation on exon 7, which plays an important role in that U2AF65 inhibits splicing of flanking introns of alternative exon alternative splicing of exon 7 (25–27). In vitro analysis using HeLa 65 in both three-exon and two-exon contexts. Similar U2AF effects nuclear extract and S100 extract demonstrates that SRSF1 pro- were observed in Fas (Apo-1/CD95) pre-mRNA. Strikingly, we dem- motes exon 7 inclusion through contacting the enhancer sequence 65 onstrate that U2AF even inhibits general splicing of adenovirus on exon 7 of SMN1 pre-mRNA, and that C-to-U mutation on major late (Ad ML) or β-globin pre-mRNA. Thus, we conclude that SMN2 pre-mRNA disrupts SRSF1 binding and then conse- 65 U2AF possesses a splicing Inhibitory function that leads to alter- quently disrupts the enhancer function of SRSF1 (28). However, native exon skipping. cell-based analysis shows a different result, indicating that SRSF1 CELL BIOLOGY does not play an essential role in SMN exon 7 splicing (29). In 65 U2AF | pre-mRNA splicing | splicing inhibition | exon exclusion | SMN contrast, cell transfection analysis demonstrates that heteroge- neous nuclear ribonucleoprotein (hnRNP) A1 interacts with the re-mRNA splicing is a process in which noncoding intron C-to-U mutation on SMN2 pre-mRNA to inhibit exon 7 splicing Psequences are removed and exon sequences are then ligated (29). A possible explanation for these different results is that different together (1, 2). Pre-mRNA splicing is carried out by spliceosome, analysis systems could provide different conclusions. a large RNA–protein complex that contains five small nuclear Although the roles of U2AF65 in alternative splicing are ver- ribonucleoproteins (U snRNPs) and more than 100 additional pro- ified to some extent, the function and mechanism are unclear. teins (3). Pre-mRNA splicing occurs in the consensus sequences at The previous reports have shown that U2AF65 roles in alterna- the 5′ splice-site, 3′ splice-site, and branch point that are necessary tive splicing are the target of alternative splicing regulatory fac- for splicing. The sequence between 3′ AG dinucleotide and branch tors, as demonstrated with increased U2AF65 binding by other point is the polypyrimidine (Py) tract that directs spliceosome as- splicing regulatory proteins (30, 31). More recently, genome- sembly on the 3′ splice-site. Alternative splicing provides an im- wide analysis has demonstrated that upstream intronic binding of portant regulatory mechanism in higher eukaryotes for multiple U2AF65 interferes with the immediate downstream 3′ splice-site proteins produced from a single gene (4, 5). 65 The U2 snRNP auxiliary factor 65 kDa (U2AF ) exists as a Significance heterodimer with U2AF35 (6). U2AF65 contains three C-terminal RNA recognition motifs (RRMs) and an N-terminal arginine/ Transcription is a biological procedure in which DNA is tran- serine-rich (RS) domain (7, 8). Using U2AF65 depletion/adding scribed to an RNA molecule. However, only fragments of this back technology with in vitro HeLa nuclear extract, it was dem- RNA are needed for protein synthesis. These fragments are onstrated that U2AF65 is an essential splicing factor (9). Whereas exons that are interrupted by introns. Introns are removed by U2AF65 binds to Py tract to promote prespliceosome assembly 35 so-called RNA splicing process. Some exons could be alterna- and branchpoint/U2 snRNA base pairing, U2AF plays a role in tively included or excluded from the final RNA molecule. In this the 3′ splice-site (10, 11). As U2AF65 prefers high C/U-rich se- 65 study, we have found that U2 snRNP auxiliary factor 65 kDa quences in the Py tract, a stronger interaction between U2AF 65 65 (U2AF ), a general splicing regulator, can significantly pro- and Py tract promotes prespliceosome assembly (12). U2AF is mote the exclusion of alternative exons. Strikingly, U2AF65 also essential in vertebrate development (13, 14). Its expression suppresses flanking intron splicing of alternative exons, and level is related to myotonic dystrophy, cystic fibrosis, and cancers even constitutive intron splicing. We deduce that the stimula- (15, 16). tory effects of U2AF65 on alternative exon exclusion are in- Proximal spinal muscular atrophy (SMA) is an autosomal re- duced by the splicing inhibitory effects of U2AF65. cessive genetic disease (17) and a leading cause of infant mor- tality. The motor neurons in the anterior horn of spinal cord are Author contributions: S.C. and H.S. designed research; S.C., H.M., T.J.L., H.N.J., and Y.L. severely damaged in patients with type 1 SMA, usually leading to performed research; S.C., Y.L., J.Z., T.O., X.Z., and H.S. analyzed data; and X.Z. and H.S. death before age 2 y as a result of a lack of respiratory support wrote the paper. (18, 19). In patients with SMA, the SMN1 gene is deleted or The authors declare no conflict of interest. mutated, whereas the SMN2 gene, a duplicate of the SMN1 gene, This article is a PNAS Direct Submission. is included (20). SMN2 genomic DNA contains a few nucleotide Freely available online through the PNAS open access option. mutations compared with SMN1 (21, 22). Full-length SMN protein 1To whom correspondence should be addressed. Email: [email protected]. functions in the U snRNP assembly/disassembly, as well as in This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. the β-actin mRNA transport in neurons (23, 24). However, the 1073/pnas.1500639112/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1500639112 PNAS Early Edition | 1of6 Downloaded by guest on September 26, 2021 of alternative or constitutive exons to cause exon skipping or A 293A C33A SH-SY5Y GM03813 inclusion (32). In the SMN pre-mRNA, it was demonstrated that 65 siRNA − − − − U2AF interacts more strongly with the SMN1 Py tract than the 6 7 8 65 6 8 SMN1 SMN2 Py tract (33). However, it is unclear how U2AF itself 6 7 8 PCR - SMN2 regulates alternative splicing. 6 8 65 RT Here we identified the function of U2AF in the alternative U2AF65 65 GAPDH splicing. Through siRNA-knockdown and overexpression of U2AF , MC3 65 IB α-tubulin we show that U2AF promotes alternative exon exclusion of both SMN2 inclusion/total (%) 12.8 13.5 37.9 14.2 15.6 45.9 27.0 28.3 61.5 46.1 48.0 65.1 ′ SD 0.2 0.3 0.5 0.4 0.3 0.6 0.3 0.1 0.3 2.0 2.0 3.0 SMN2 and SMN1 pre-mRNA. Mutations of 5 splice-site in exon 7 1 2 3 4 5 6 7 8 9 10 11 12 to a higher score sequence abolished the U2AF65 effects. Highly 65 B 293A C33A SH-SY5Y GM03813 expressed U2AF also represses splicing of exon 7, flanking introns uucuuuuuuuuuuuuuuuuuuuuuugag 65 in three or two exon contexts. Strikingly, U2AF also inhibits intron − − − − 6 7 8 β 6 8 splicing of adenovirus major late (Ad ML) and -globin pre-mRNA. 6 7 8 1kb 65 515nt RT-PCR GAPDH In addition, U2AF selectively increases its own binding on the SMN2 Flag IB α-tubulin weaker Py tract sequence, but not the stronger Py tract. Our Skipping/total (%) 48.8 46.8 95.6 47.9 50.3 95.1 47.4 47.9 95.6 58.8 60.9 96.5 65 SD 0.5 1.0 1.0 1.5 0.3 0.3 3.0 2.2 0.9 0.9 1.5 0.8 results support the conclusion that the U2AF activity in pro- 1 2 3 4 5 6 7 8 9 10 11 12 moting alternative exon skipping comes from its own splicing inhibitory activity. C 293A C33A SH-SY5Y GM03813 uucuuuuuuuuuuuuuuuuuuuuuugag − − − − Results 6 7 8 515nt 6 8 6 7 8 65 RT-PCR 1kb GAPDH U2AF Stimulates Alternative Exon Exclusion. To determine the role Flag of U2AF65 in alternative exon spicing, we first applied siRNA- SMN1 IB α-tubulin 65 65 Skipping/total (%) 4.1 3.8 44.6 3.1 2.8 31.5 4.9 2.9 30.8 13.9 17.8 53.4 directed knockdown of U2AF .
Load more

Recommended publications
  • Exon Skipping by Overexpression of a Drosophila Heterogeneous Nuclear
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 1822-1825, March 1995 Biochemistry Exon skipping by overexpression of a Drosophila heterogeneous nuclear ribonucleoprotein in vivo (alternative splicing/dopa decarboxylase) JIE SHEN*, KAI Zut, CYNTHIA L. CASSt, ANN L. BEYERt, AND JAY HIRSH*t Departments of *Biology and tMicrobiology, University of Virginia, Charlottesville, VA 22903 Communicated by Oscar L. Miller, Jr., University of Virginia, Charlottesville, VA, November 28, 1994 (received for review September 15, 1994) ABSTRACT Heterogeneous nuclear ribonucleoproteins and a glycine-rich carboxyl-terminal domain (22-27). How- (hnRNPs) are abundant RNA-binding proteins that are im- ever, none of these Drosophila hnRNPs display sufficient plicated in splicing regulation. Here we investigate the role of sequence similarity to any vertebrate hnRNPs to determine a Drosophila hnRNP in splicing regulation in living animals. whether they are homologues of distinctive vertebrate We find that overexpression of the Drosophila hnRNP hnRNPs. The HRB98DE protein, which has 58% sequence HRB98DE leads to skipping of all internal exons in the identity with the rat Al protein in the RNA-binding domains, Drosophila dopa decarboxylase (Ddc) pre-mRNA in vivo. These is probably the closest relative of Al in D. melanogaster (25). results indicate that HRB98DE has a splicing activity that The HRB98DE gene encodes four protein isoforms derived promotes use of terminal splice sites. The effect of excess from alternative splicing and alternative use of 5' exons 1A or HRB98DE onDdc splicing is transient, even though high levels 1B. However, these HRB98DE isoforms share identical RNA- of HRB98DE persist for at least 24 hr. This suggests that binding domains.
    [Show full text]
  • EYS Mutations and Implementation of Minigene Assay for Variant
    www.nature.com/scientificreports OPEN EYS mutations and implementation of minigene assay for variant classifcation in EYS‑associated retinitis pigmentosa in northern Sweden Ida Maria Westin1, Frida Jonsson1, Lennart Österman1, Monica Holmberg1, Marie Burstedt2 & Irina Golovleva1* Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous group of inherited retinal degenerations. The ortholog of Drosophila eyes shut/spacemaker, EYS on chromosome 6q12 is a major genetic cause of recessive RP worldwide, with prevalence of 5 to 30%. In this study, by using targeted NGS, MLPA and Sanger sequencing we uncovered the EYS gene as one of the most common genetic cause of autosomal recessive RP in northern Sweden accounting for at least 16%. The most frequent pathogenic variant was c.8648_8655del that in some patients was identifed in cis with c.1155T>A, indicating Finnish ancestry. We also showed that two novel EYS variants, c.2992_2992+6delinsTG and c.3877+1G>A caused exon skipping in human embryonic kidney cells, HEK293T and in retinal pigment epithelium cells, ARPE‑19 demonstrating that in vitro minigene assay is a straightforward tool for the analysis of intronic variants. We conclude, that whenever it is possible, functional testing is of great value for classifcation of intronic EYS variants and the following molecular testing of family members, their genetic counselling, and inclusion of RP patients to future treatment studies. Retinitis pigmentosa (RP, MIM 268000) is a clinically and genetically heterogeneous group of inherited retinal degenerations (IRDs) causing primarily deterioration of the rod photoreceptors with subsequent worsening of the cones. It is classifed into two forms: syndromic (afecting other organs) and non-syndromic (not afect- ing other organs).
    [Show full text]
  • Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
    Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 8/25/20 -- FDA grants Priority Review Status and sets regulatory action date for February 25, 2021 -- -- FDA has indicated it does not currently plan to hold an advisory committee meeting to discuss the application -- -- Received FDA's conditional approval of AMONDYS 45™ as brand name for casimersen -- -- Casimersen has been studied for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne -- CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) seeking accelerated approval for casimersen (SRP-4045) and provided a regulatory action date of February 25, 2021. The FDA has indicated it does not currently plan to hold an advisory committee to discuss the application. In addition, the Company has received conditional approval of AMONDYS 45 as the brand name for casimersen. Casimersen, a phosphorodiamidate morpholino oligomer (PMO), is engineered to treat patients with Duchenne muscular dystrophy (DMD) who have genetic mutations that are amenable to skipping exon 45 of the dystrophin gene. The Company submitted its NDA filing in June 2020 and requested priority review, which the FDA granted. The NDA included data from the casimersen arm of the ESSENCE study (also known as Study 4045-301), a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of casimersen in patients amenable to skipping exons 45.
    [Show full text]
  • Analysis of Exonic Mutations Leading to Exon Skipping in Patients with Pyruvate Dehydrogenase E1␣ Deficiency
    0031-3998/00/4806-0748 PEDIATRIC RESEARCH Vol. 48, No. 6, 2000 Copyright © 2000 International Pediatric Research Foundation, Inc. Printed in U.S.A. Analysis of Exonic Mutations Leading to Exon Skipping in Patients with Pyruvate Dehydrogenase E1␣ Deficiency ALESSANDRA KUPPER CARDOZO, LINDA DE MEIRLEIR, INGE LIEBAERS, AND WILLY LISSENS Center for Medical Genetics [A.K.C., L.D.M., I.L., W.L.] and Pediatric Neurology [L.D.M.], University Hospital, Vrije Universiteit Brussel, 1090 Brussels, Belgium. ABSTRACT The pyruvate dehydrogenase (PDH) complex is situated at a mutations that either reverted or disrupted the wild-type pre- key position in energy metabolism and is responsible for the dicted pre-mRNA secondary structure of exon 6, we were unable conversion of pyruvate to acetyl CoA. In the literature, two to establish a correlation between the aberrant splicing and unrelated patients with a PDH complex deficiency and splicing disruption of the predicted structure. The mutagenic experiments out of exon 6 of the PDH E1␣ gene have been described, described here and the silent mutation found in one of the although intronic/exonic boundaries on either side of exon 6 patients suggest the presence of an exonic splicing enhancer in were completely normal. Analysis of exon 6 in genomic DNA of the middle region of exon 6 of the PDH E1␣ gene. (Pediatr Res these patients revealed two exonic mutations, a silent and a 48: 748–753, 2000) missense mutation. Although not experimentally demonstrated, the authors in both publications suggested that the exonic muta- tions were responsible for the exon skipping. In this work, we Abbreviations were able to demonstrate, by performing splicing experiments, ESE, exonic splicing enhancer that the two exonic mutations described in the PDH E1␣ gene mfe, minimum free energy lead to aberrant splicing.
    [Show full text]
  • Increased Dystrophin Production with Golodirsen in Patients with Duchenne Muscular Dystrophy
    Published Ahead of Print on March 5, 2020 as 10.1212/WNL.0000000000009233 ARTICLE OPEN ACCESS CLASS OF EVIDENCE Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy Diane E. Frank, PhD, Frederick J. Schnell, PhD, Cody Akana, BS, Saleh H. El-Husayni, BS, Correspondence Cody A. Desjardins, PhD, Jennifer Morgan, PhD, Jay S. Charleston, PhD, Valentina Sardone, PhD, Dr. Muntoni Joana Domingos, MD, George Dickson, PhD, Volker Straub, MD, Michela Guglieri, Eugenio Mercuri, MD, [email protected] Laurent Servais, PhD, and Francesco Muntoni, MD, on behalf of the SKIP-NMD Study Group Neurology® 2020;00:1-13. doi:10.1212/WNL.0000000000009233 Abstract MORE ONLINE Objective Class of Evidence To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen- Criteria for rating treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. therapeutic and diagnostic studies Methods NPub.org/coe Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation. Safety and pharmacokinetics were primary and secondary objectives of part 1. Primary biological outcome measures of part 2 were blinded exon skipping and dystrophin protein production on muscle biopsies (baseline, week 48) evaluated, respectively, using reverse transcription PCR and Western blot and immunohistochemistry. Results Twelve patients were randomized to receive golodirsen (n = 8) or placebo (n = 4) in part 1. All from part 1 plus 13 additional patients received 30 mg/kg golodirsen in part 2. Safety findings were consistent with those previously observed in pediatric patients with DMD.
    [Show full text]
  • Duchenne Population Potentially Amenable to Exon Skipping
    Exon 8, 2% Exon 55, 2% Exon 43, 4% Exon 52, 4% Exon 50, 4% Duchenne Population Potentially Amenable to Exon Skipping May not be Exon 44 amenable Exon skipping is a potential treatment approach to correct and restore production of to exon 6% Percent of Duchenne skipping, dystophin. For specific genetic mutations it allows the body to make a shorter, usable ~30% population potentially Exon 45 dystophin. Exon skipping is not a cure for Duchenne, but it may make the effects less 8% amenable to exon severe. No single drug will help everyone with Duchenne. It is estimated that skipping 13% of Duchenne patients have a mutation amenable to skipping exon 51. Exon Other exon skipping may eventually apply to 60-80 percent of Duchenne patients. Exon 53 skips, 8% ~20% Exon 53 Skip-amenable Exon 45 Skip-amenable 13% Exon 51 3-52 4-52 5-52 6-52 9-52 7-44 10-52 11-52 13-52 14-52 15-52 16-52 17-52 19-52 12-44 18-44 Exon 51 Skip-amenable 21-52 23-52 24-52 25-52 26-52 27-52 28-52 29-52 44 46 46-47 46-48 46-49 3-50 4-50 5-50 6-50 9-50 30-52 31-52 32-52 33-52 34-52 35-52 36-52 37-52 38-52 39-52 46-51 46-53 46-55 46-57 46-59 10-50 11-50 13-50 14-50 15-50 16-50 17-50 19-50 40-52 41-52 42-52 43-52 45-52 47-52 48-52 49-52 46-60 46-67 46-69 46-75 46-78 21-50 23-50 24-50 25-50 26-50 27-50 28-50 29-50 50-52 52 54-58 54-61 54-63 54-64 54-66 54-76 54-77 30-50 31-50 32-50 33-50 34-50 35-50 36-50 37-50 38-50 39-50 40-50 41-50 42-50 43-50 45-50 47-50 48-50 49-50 Exon 50 Skip-amenable Exon 52 Skip-amenable 50 52 52-58 52-61 52-63 52-64 52-66 52-76 52-77 2-49 8-49 2-51
    [Show full text]
  • Cellular Minigene Models for the Study of Allelic Expression of the Tau Gene and Its Role in Progressive Supranuclear Palsy
    CELLULAR MINIGENE MODELS FOR THE STUDY OF ALLELIC EXPRESSION OF THE TAU GENE AND ITS ROLE IN PROGRESSIVE SUPRANUCLEAR PALSY Victoria Anne Kay Thesis submitted in the fulfilment of the degree of Doctor of Philosophy Reta Lila Weston Institute of Neurological Studies Institute of Neurology University College London March 2013 Declaration I, Victoria Kay, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract Progressive supranuclear palsy (PSP) belongs to a group of neurodegenerative disorders that are characterised by hallmark pathology consisting of intra-neuronal aggregates of the microtubule-associated protein, tau. In PSP, these aggregates are almost exclusively composed of one of the two major tau protein isoform groups normally expressed at similar levels in the healthy brain, indicating a role for altered isoform regulation in PSP aetiology. Although no causal mutations have been identified, common variation within the gene encoding tau, MAPT, has been highly associated with PSP risk. The A-allele of the rs242557 single nucleotide polymorphism has been repeatedly shown to significantly increase the risk of developing PSP. Its location within a distal region of the MAPT promoter region is significant, with independent studies – including this one – demonstrating that the rs242557-A allele alters the function of a transcription regulatory domain. As transcription and alternative splicing processes have been shown to be co-regulated in some genes, it was hypothesised that the rs242557-A allele could directly affect MAPT alternative splicing through its differential effect on transcription.
    [Show full text]
  • Duchenne Muscular Dystrophy
    A Guide for Individuals and Families What is... Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) is the Because the DMD gene is located on the most common form of muscular dystrophy. X-chromosome, it primarily affects males, It is a genetic disorder characterized by while females typically are carriers. progressive weakness However, some females can experience and degeneration of the skeletal muscles that varying degrees of physical Duchenne control movement. symptoms and are therefore called manifesting carriers. Duchenne affects approximately1 in 5,000 live male births. It is estimated that DMD typically is inherited through the about 20,000 children are diagnosed with mother; however, in about 25% of cases, the Duchenne globally each year. disease occurs spontaneously in people who do not have a family history of DMD. DMD is classified as a dystrophinopathy, a muscle disease that results from the There is no cure for DMD, but medications deficiency of a protein called dystrophin. and therapy can help manage some symptoms and potentially slow the course of In Duchenne, a mutation in the DMD the disease. gene interferes with the production of the dystrophin protein, which is needed to form and maintain healthy muscle. Lack of the dystrophin protein in muscle cells causes them to be fragile and easily damaged. What are the signs and symptoms of DMD? DMD is a multi-systemic condition affecting many parts of the body and resulting in atrophy of the skeletal, cardiac (heart), and pulmonary (lung) muscles. Nervous system Skeleton
    [Show full text]
  • Splicing Inhibition of U2AF Leads to Alternative Exon Skipping
    Splicing inhibition of U2AF65 leads to alternative exon skipping Sunghee Choa, Heegyum Moona, Tiing Jen Loha, Ha Na Janga, Yongchao Liua, Jianhua Zhoub, Takbum Ohnc, Xuexiu Zhenga, and Haihong Shena,1 aSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Korea; bJiangSu Key Laboratory of Neuroregeneration, Nantong University, Nantong 226001, China; and cDepartment of Cellular & Molecular Medicine, College of Medicine, Chosun University, Gwangju 501-759, Korea Edited by Michael R. Green, University of Massachusetts Medical School, Worcester, MA, and approved June 11, 2015 (received for review January 11, 2015) U2 snRNP auxiliary factor 65 kDa (U2AF65) is a general splicing factor mutations in SMN2 pre-mRNA cause predominantly skipping of that contacts polypyrimidine (Py) tract and promotes prespliceo- exon 7, which produces SMNΔ7, a truncated and less stable pro- some assembly. In this report, we show that U2AF65 stimulates al- tein with reduced self-oligomerization activity. Alternative exon 7 ternative exon skipping in spinal muscular atrophy (SMA)-related splicing of SMN pre-mRNA was modulated by orchestrated RNA– survival motor neuron (SMN) pre-mRNA. A stronger 5′ splice-site protein and protein–protein interactions, secondary structures of mutation of alternative exon abolishes the stimulatory effects of RNA, and RNA sequences (25–27). Among the mutations on U2AF65. U2AF65 overexpression promotes its own binding only on SMN2 pre-mRNA, the most functionally understood one is the the weaker, not the stronger, Py tract. We further demonstrate C-to-U point mutation on exon 7, which plays an important role in that U2AF65 inhibits splicing of flanking introns of alternative exon alternative splicing of exon 7 (25–27).
    [Show full text]
  • 213026Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213026Orig1s000 OTHER REVIEW(S) IMMUNOGENICITY ASSESSMENT Application Type NDA Application Number 213026 Submit Date 01/10/2020 Received Date 01/10/2020 Division/Office CDER/OND/ON/DNI Review Completion Date 01/10/2021 Product Name Casimersen Proposed Proprie tary AMONDYS 45 Name Error! Bookmark not defined. Pharmacologic Class PMO exon Skipping Applicant Sarepta Therapeutics, Inc. (b) (4) Applicant Proposed Duchenne muscular dystrophy (DMD) in Indication(s) patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. Immunogenicity Assessors Primary Assessor(s) Seth Thacker PhD Secondary Assessor (s) Daniela Verthelyi PhD MD Assessor Recommendation: The sponsor has submitted data for anti-dystrophin antibodies in the casimersen trials. These data were generated using assays that were developed for assessing anti-dystrophin antibodies in patients treated with eteplirsen and golodirsen and have already been deemed fit for use. The sponsor submitted anti-dystrophin ADA data for Study 4045-101, which had 12 patients enrolled No positive samples were found. The FPR for these assays in Study 4045-101 were 1.3%(IgG), 7.9% (IgE), and 39% (IgM) as calculated by the assessor. The sponsors has not submitted an assay for the detection of Casimersen-specific ADAs or provided a plan on how they assess the risk associated with the generation of novel epitopes in the dystrophin formed by exon 45 skipping. PMRs will be issued to the sponsor to develop and validate the assays and to assess the patients in study 4045-101 and 4045-301 for Abs to the product and to the peptide generated through the exon skipping strategy.
    [Show full text]
  • Medical Policy Eteplirsen (Exondys 51™) Injection
    Medical Policy Eteplirsen (Exondys 51™) Injection SPECIALTY GUIDELINE MANAGEMENT Eteplirsen (Exondys 51™) Background: Eteplirsen (Exondys 51™) is a new antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD), a recessive X-linked myopathy in which a person is unable to properly synthesize dystrophin, a protein essential to the maintenance of muscle cell membrane integrity, and thus suffers progressive muscle deterioration. Eteplirsen is designed to facilitate functional dystrophin production by causing gene expression to skip exon 51 on the DMD gene, the exon associated with approximately 13% of DMD-causing mutations. Authorization: Prior authorization is required for eteplirsen (Exondys 51™) requested by members enrolled in commercial (HMO, POS and PPO) products. Policy and Coverage Criteria: Initiation of Therapy: Harvard Pilgrim Health Care (HPHC) considers initiation of injected eteplirsen (Exondys 51™) as reasonable and medically necessary for the management of Duchenne muscular dystrophy (DMD) for a maximum of six months when medical record documentation confirm ALL of the following; A. Member DMD is due to mutation of the DMD gene amenable to exon 51 skipping and no other DMD- associated mutations; B. Ongoing use of a stable dose of corticosteroids going back at least six months or a contraindication to corticosteroids; C. Member is able to average a 180 meter 6-minute walk test (6MWT); D. Assessment and prescription were performed by a physician specializing in DMD; E. Dosage and use is consistent
    [Show full text]
  • An Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence
    Nucleic Acids Research, 1993, Vol. 21, No. 25 5901-5908 Stimulation of gene expression by introns: conversion of an inhibitory intron to a stimulatory intron by alteration of the splice donor sequence Martin Korb+, Yunbo Ke and Lee F.Johnson* Departments of Molecular Genetics and Biochemistry, The Ohio State University, Columbus, OH 43210, USA Received September 16, 1993; Revised and Accepted November 18, 1993 GenBank accession no. L11364 ABSTRACT Efficient expression of many mammalian genes Introns have been shown to be directly responsible for a variety depends on the presence of at least one intron. We of qualitative changes in gene expression. For example, previously showed that addition of almost any of the alternative splicing of introns from primary transcripts can give introns from the mouse thymidylate synthase (TS) gene rise to multiple mRNA (and protein) species from a single gene to an intronless TS minigene led to a large increase In (reviewed in 3). expression. However, addition of intron 4 led to a Introns can also have quantitative effects on gene expression. reduction In minigene expression. The goal of the Some introns contain promoter or enhancer elements and present study was to determine why TS intron 4 was stimulate expression by increasing the rate of gene transcription unable to stimulate expression. Insertion of intron 4 (4-12). Regulating the efficiency of intron splicing also appears into an intron-dependent derivative of the ribosomal to play an important role in the autogenous regulation of yeast protein L32 gene did not lead to a significant increase ribosomal protein genes (13), and in the growth-regulated in expression, suggesting that its inability to stimulate expression of several mammalian genes for S-phase proteins expression was due to sequences within the intron.
    [Show full text]